Business Description
Chengdu Easton Biopharmaceuticals Co Ltd
ISIN : CNE100004397
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.1 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.97 | |||||
Interest Coverage | 56.93 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.07 | |||||
Beneish M-Score | -1.68 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.4 | |||||
3-Year EBITDA Growth Rate | 4.5 | |||||
3-Year EPS without NRI Growth Rate | 5 | |||||
3-Year Book Growth Rate | 7.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 36.84 | |||||
Future 3-5Y Total Revenue Growth Rate | 23.26 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.63 | |||||
9-Day RSI | 52.09 | |||||
14-Day RSI | 53.44 | |||||
6-1 Month Momentum % | -12.78 | |||||
12-1 Month Momentum % | -10.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.66 | |||||
Quick Ratio | 2.42 | |||||
Cash Ratio | 2 | |||||
Days Inventory | 225.81 | |||||
Days Sales Outstanding | 44.88 | |||||
Days Payable | 233.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.59 | |||||
Dividend Payout Ratio | 0.43 | |||||
Forward Dividend Yield % | 1.59 | |||||
5-Year Yield-on-Cost % | 1.54 | |||||
Shareholder Yield % | 0.22 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 77.85 | |||||
Operating Margin % | 18.62 | |||||
Net Margin % | 19.62 | |||||
FCF Margin % | 6.87 | |||||
ROE % | 9.31 | |||||
ROA % | 7.3 | |||||
ROIC % | 13.12 | |||||
ROC (Joel Greenblatt) % | 21.11 | |||||
ROCE % | 9.76 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 27.1 | |||||
Forward PE Ratio | 19.33 | |||||
PE Ratio without NRI | 27.44 | |||||
Price-to-Owner-Earnings | 135.21 | |||||
PEG Ratio | 2.8 | |||||
PS Ratio | 5.33 | |||||
PB Ratio | 2.46 | |||||
Price-to-Tangible-Book | 2.55 | |||||
Price-to-Free-Cash-Flow | 76.66 | |||||
Price-to-Operating-Cash-Flow | 27.51 | |||||
EV-to-EBIT | 19.82 | |||||
EV-to-EBITDA | 19.82 | |||||
EV-to-Revenue | 4.19 | |||||
EV-to-FCF | 61.93 | |||||
Price-to-Graham-Number | 1.76 | |||||
Price-to-Net-Current-Asset-Value | 5.5 | |||||
Price-to-Net-Cash | 9.56 | |||||
Earnings Yield (Greenblatt) % | 5.05 | |||||
FCF Yield % | 1.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Chengdu Easton Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 1,231.277 | ||
EPS (TTM) (Â¥) | 1.372 | ||
Beta | 0.34 | ||
Volatility % | 40.83 | ||
14-Day RSI | 53.44 | ||
14-Day ATR (Â¥) | 2.236709 | ||
20-Day SMA (Â¥) | 35.699 | ||
12-1 Month Momentum % | -10.6 | ||
52-Week Range (Â¥) | 28.11 - 46.84 | ||
Shares Outstanding (Mil) | 176.53 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Chengdu Easton Biopharmaceuticals Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Chengdu Easton Biopharmaceuticals Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Chengdu Easton Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513)'s stock price today?
When is next earnings date of Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513)?
Does Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |